PetVisionPro | PetVision

where to buy

Contains no

N-A-C*

* NAC = N- acetyl-Carnosine

Healthy eyes help pets see the most important things in life. ADER's PetVisionPro® gives you an economical, easy-to-administer solution for reducing lens opacity and improving eye health in your patients.

PetVisionPro®

Helps reduce lens opacity
Enhances eye lubrication
Helps maintain eye health

AN AFFORDABLE ALTERNATIVE TO

Veterinarians have limited options for managing patients with opacity of the lens caused by protein glycation.

PetVisionPro offers a cost-effective management

solution for lens opacity before referring

patients to specialists for invasive and

expensive surgery.

SHOULDN'T SCARE PET OWNERS AWAY

It's a choice owners of aging pets will have to face: expensive and invasive surgery or watching their companions' sight fade. With PetVisionPro you can offer a proven management solution before an expensive referral. In addition to saving your clients the cost of expensive surgery PetVisionPro:

Maintains eye health for up to six months
Improves cosmetic appearance of the eye
Is easy to administer for improved compliance

How does PetVisionPro® do it?

PetVisionPro is a patented formulation of amino acids and antioxidants in a preserved sterile solution that works to dissolve glycated proteins. The easy-to-use PetVisionPro® applicator improves client adherence by making it simple to administer 1-2 drops, 2 to 3 times daily, in the affected eye(s).

Pet owners are advised to revisit the veterinarian after 36 days of treatment
Treat for up to 180 days as needed on the veterinarian's assessment of treatment

IN AS LITTLE AS 36 DAYS.

PROVEN

RESULTS

An in vivo study of 76 canine eyes showed that PetVisionPro® is demonstrated to reduce lens opacity by as much as 95%.

Our products are manufactured in accordance with the requirements as set forth by the Food and Drug Administration monograph for ophthalmic products. The statements contained herein have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Cloudiness was studied by location in the eye and by the age of the eye. The results*:

SUBCAPSULAR POSTERIOR CLOUDINESS

95% OPACITY REDUCTION IN 41 EYES

ANTERIOR CORTICAL CLOUDINESS

90% OPACITY REDUCTION IN 9 EYES

MATURE OPACITY

90% OPACITY REDUCTION IN 22 EYES

MULTIPLE TYPES OF LENS OPACITY

95% OPACITY REDUCTION IN 4 EYES